Marking another step in Dr Reddy’s diverse corporate strategy, the company has signed a memorandum of understanding with Kainomyx for the development and commercialization of anti-malarials in multiple markets.
Dr. Reddy's Laboratories and its subsidiary CRDMO Aurigene Pharmaceutical Services have signed a non-binding memorandum of understanding with the US-based firm Kainomyx for the development and commercialization of anti-malarial drugs in the US, Europe and low and middle-income countries.
Under terms of the deal, Kainomyx will handle both the technical strategy and tasks linked to the drug discovery and...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
